1.25Open1.25Pre Close0 Volume7 Open Interest3.00Strike Price0.00Turnover155.91%IV3.16%PremiumDec 20, 2024Expiry Date1.12Intrinsic Value100Multiplier19DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type0.8597Delta0.1527Gamma3.30Leverage Ratio-0.0089Theta0.0012Rho2.83Eff Leverage0.0021Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet